Global Ankylosing Spondylitis Market Revenue Grows at a CAGR of 6.68%

Introduction

Straits Research released its highly anticipated report, “Global Ankylosing Spondylitis Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 6.64 billion in 2025 and is anticipated to grow to USD 11.84 billion by 2034, growing at a CAGR of 6.68% from 2026-2034.

Market Dynamics

The ankylosing spondylitis market continues to expand as healthcare systems strengthen their focus on early recognition of chronic spinal inflammation and broaden access to advanced therapeutics across diverse care settings. Growth within this landscape is shaped by evolving diagnostic protocols, rising acceptance of biologics and biosimilars, and increasing emphasis on long-term disease control supported by structured monitoring frameworks.

A primary driver for market expansion is the increasing transition toward targeted treatment pathways that align with individual disease trajectories. Rheumatology specialists increasingly initiate therapy based on the progression of inflammation rather than delayed intervention models that once depended solely on visible structural changes. This shift encourages earlier adoption of biologics and advanced oral treatments among patients who require sustained control of axial symptoms. Broader availability of specialty centers and rising awareness campaigns conducted by clinical associations further contribute to smoother referral pathways, creating continuity between initial consultation and initiation of treatment. As a result, demand for advanced therapeutics continues to rise across both developed and emerging healthcare markets.

Despite this positive momentum, the market encounters a restraint due to variation in access to specialized diagnostic resources across community healthcare networks. Smaller hospitals frequently encounter delays when conducting advanced imaging or biomarker testing, which can extend the time required to confirm disease classification. These delays create extended intervals before patients receive targeted treatment, leading to uneven adoption patterns at regional and national levels. Limitations in trained rheumatology personnel also contribute to slower evaluation cycles, reinforcing gaps that persist within rural and semi-urban health systems.

An attractive opportunity is emerging through the expansion of biomarker-guided monitoring tools that support the prediction of disease activity and treatment response. Research institutions and specialty hospitals increasingly explore serum markers, genetic profiles, and digital mobility data to refine prognostic models. These platforms support personalized treatment adjustments and create pathways for earlier therapy modification when disease activity rises. As integration of predictive technologies progresses, the market stands to benefit from improved management frameworks that elevate long-term outcomes for patients with ankylosing spondylitis.

Market Highlights

• Drug Class: Based on Drug Class, the TNF inhibitors segment dominated the market with 59.81% share.
• Disease Stage: Based on Disease Stage, the moderate ankylosing spondylitis segment dominated the market with 49.21% share.
• Diagnostic Method: Based on the Diagnostic Method, the MRI segment dominated the market with a 41.21% share.
• Distribution Channel: Based on the Distribution Channel, the Hospital Pharmacy segment dominated the market with 48.99%.
• Regional Insights: North America held a dominant share of the global market, accounting for 58.24% share in 2025.

Competitive Players

1. AbbVie Inc.
2. Novartis Pharmaceuticals Corporation
3. UCB S.A.
4. Amgen Inc.
5. Pfizer Inc.
6. Eli Lilly and Company
7. Janssen-Cilag Limited
8. Merck & Co., Inc.
9. Boehringer Ingelheim Pharmaceuticals, Inc. 
10. CELLTRION INC.
11. Samsung Bioepis
12. Reliance Life Sciences
13. Zydus Lifesciences Limited
14. Gilead Sciences, Inc. 
15. Hoffmann-La Roche Ltd
16. Others

Recent Developments

April 2025: Biocad, together with the Russian National Research Medical University of Pirogov and the Institute of Bioorganic Chemistry, reported Seniprutug as a domestic drug for the treatment of ankylosing spondylitis. The drug was already registered earlier and was planned to reach patients across 45 Russian regions, with the ability to relieve symptoms and slow disease progression.

Segmentation

1. By Drug Class (2026-2034)
   1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
      1. TNF Inhibitors
      2. Humira
      3. Simponi
      4. Remicade
      5. Enbrel
      6. Cimzia
      7. Other TNF Inhibitors
   2. Other Drug Classes
2. By Disease Stage (2026-2034)
   1. Early-Stage Ankylosing Spondylitis
   2. Moderate Ankylosing Spondylitis
   3. Severe / Advanced Ankylosing Spondylitis
3. By Diagnostic Method (2026-2034)
   1. MRI
   2. X-Ray Radiography
   3. Blood Biomarkers (CRP/ESR)
   4. HLA-B27 Genetic Testing
   5. Digital Spine Monitoring Tools
4. By Distribution Channel (2026-2034)
   1. Hospital Pharmacy
   2. Retail Pharmacy
   3. Others